Gérald Simonneau

Q: What Schools Are Affiliated With Gérald Simonneau

Gérald Simonneau is affiliated with the following schools: Paris-Saclay University, University of Sydney, Baylor College of Medicine

Gérald Simonneau's AcademicInfluence.com Rankings

Gérald Simonneau

Philosophy

#3405

World Rank

#5515

Historical Rank

Logic

#1138

World Rank

#1805

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Gérald Simonneau Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gérald Simonneau's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Updated clinical classification of pulmonary hypertension. (2009) (3396)
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. (2016) (2682)
[2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. (2015) (2327)
Haemodynamic definitions and updated clinical classification of pulmonary hypertension (2019) (2124)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2015) (2007)
Sildenafil citrate therapy for pulmonary arterial hypertension. (2005) (1939)
Guidelines for the diagnosis and treatment of pulmonary hypertension (2009) (1630)
Pulmonary arterial hypertension in France: results from a national registry. (2006) (1495)
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. (1998) (1486)
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. (2002) (1423)
Inhaled iloprost for severe pulmonary hypertension. (2002) (1369)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. (2002) (1365)
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era (2010) (1265)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study (2001) (1225)
Pulmonary arterial hypertension (2013) (1158)
Macitentan and morbidity and mortality in pulmonary arterial hypertension. (2013) (1116)
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. (1996) (1112)
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension (2005) (1078)
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. (2013) (1074)
Bosentan therapy for pulmonary arterial hypertension. (2002) (1071)
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. (2004) (1056)
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. (1995) (1019)
Tadalafil Therapy for Pulmonary Arterial Hypertension (2009) (957)
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial (2008) (882)
[Updated clinical classification of pulmonary hypertension]. (2014) (854)
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. (1996) (850)
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015) (819)
Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry (2011) (805)
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. (1995) (782)
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. (1997) (779)
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. (2001) (683)
Selexipag for the Treatment of Pulmonary Arterial Hypertension. (2014) (641)
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. (2002) (636)
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 (2004) (635)
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension (2010) (614)
Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. (2011) (603)
Survival with first-line bosentan in patients with primary pulmonary hypertension (2005) (600)
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. (2001) (579)
Increased plasma serotonin in primary pulmonary hypertension. (1995) (565)
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines (2004) (558)
Pulmonary hypertension due to left heart diseases. (2013) (556)
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib (2012) (539)
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. (2008) (522)
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008) (513)
[Treatment of pulmonary arterial hypertension]. (2004) (509)
Clinical classification of pulmonary hypertension. (2001) (508)
Ambrisentan therapy for pulmonary arterial hypertension. (2005) (491)
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study (2013) (481)
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension (2017) (454)
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. (2008) (440)
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension (2002) (426)
Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study (2002) (425)
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. (2008) (424)
Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry (2016) (415)
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome (2009) (400)
Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension (2014) (390)
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. (2003) (384)
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. (2007) (378)
New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. (2004) (376)
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis (2005) (355)
Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules (2016) (349)
EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension (2013) (344)
Mutations of the TGF‐β type II receptor BMPR2 in pulmonary arterial hypertension (2006) (344)
Pulmonary vascular disorders in portal hypertension. (1998) (337)
Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. (2008) (336)
Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. (2010) (329)
Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. (2006) (327)
Pulmonary hypertension in chronic lung diseases. (2013) (321)
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. (2000) (317)
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil (2006) (315)
Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. (2003) (313)
Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. (2007) (312)
Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. (1998) (306)
Pulmonary Veno-Occlusive Disease: Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology (2008) (306)
Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis (1994) (305)
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. (2004) (303)
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. (2008) (303)
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. (2006) (301)
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. (2003) (300)
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study (2014) (299)
Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. (2011) (299)
Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. (2012) (293)
Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. (1981) (291)
Chemokine RANTES in severe pulmonary arterial hypertension. (2002) (290)
Thrombotic risk factors in pulmonary hypertension. (2000) (284)
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. (1998) (282)
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (2012) (278)
Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. (2006) (275)
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. (2010) (275)
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. (2004) (269)
An overview of the 6th World Symposium on Pulmonary Hypertension (2019) (268)
Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension (2014) (261)
The pathophysiology of chronic thromboembolic pulmonary hypertension (2017) (261)
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. (2022) (260)
Severe pulmonary hypertension in histiocytosis X. (2000) (252)
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis (2016) (249)
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. (1995) (248)
Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. (2000) (248)
Severe Pulmonary Hypertension during Pregnancy: Mode of Delivery and Anesthetic Management of 15 Consecutive Cases (2005) (247)
Primary pulmonary hypertension and fenfluramine use. (1993) (247)
Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. (2004) (245)
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. (2004) (243)
Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension (2004) (242)
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) (2014) (242)
Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. (1994) (240)
CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension (2002) (239)
Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. (2004) (238)
Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. (1993) (234)
[Pulmonary hypertension in chronic lung diseases]. (2014) (233)
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension (2009) (229)
Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. (2001) (224)
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. (2011) (223)
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension (2006) (218)
Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension: Results of a Multicenter European Analysis of Pulmonary Artery Pressure Response to Exercise and Hypoxia (2009) (217)
Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. (2007) (215)
Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. (2007) (212)
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol (2005) (210)
Portopulmonary hypertension: survival and prognostic factors. (2008) (210)
Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension (2004) (208)
Diaphragm dysfunction induced by upper abdominal surgery. Role of postoperative pain. (1983) (207)
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives (2002) (206)
Criteria for diagnosis of exercise pulmonary hypertension (2015) (204)
Splenectomy and chronic thromboembolic pulmonary hypertension (2005) (200)
Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. (2009) (197)
Updated clinical classification of pulmonary hypertension. (2009) (197)
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. (2006) (194)
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension (2007) (191)
Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature (2014) (191)
Chronic thromboembolic pulmonary hypertension (2004) (190)
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. (2017) (183)
A hemodynamic study of pulmonary hypertension in sickle cell disease. (2011) (183)
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. (2016) (181)
C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. (2011) (181)
Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. (2001) (179)
Targeted therapies in pulmonary arterial hypertension. (2014) (179)
[Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. (2005) (178)
HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era (2010) (177)
Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. (1990) (175)
[Treatment of pulmonary arterial hypertension]. (2014) (175)
Long term imatinib treatment in pulmonary arterial hypertension (2006) (173)
Chronic thromboembolic pulmonary hypertension. (2004) (172)
Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. (1997) (171)
Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. (2001) (170)
Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension (2005) (167)
Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension (2007) (166)
ERS statement on chronic thromboembolic pulmonary hypertension (2020) (166)
High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. (1999) (165)
Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. (1998) (165)
Pulmonary Arterial Hypertension: A Rare Complication of Primary Sjögren Syndrome: Report of 9 New Cases and Review of the Literature (2007) (165)
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. (1994) (159)
Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. (2004) (158)
EFFECTS OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULM HT: A RANDOMIZED PLACEBO CONTROLLED STUDY (2001) (158)
Pulmonary veno-occlusive disease (2016) (156)
CX(3)C chemokine fractalkine in pulmonary arterial hypertension. (2002) (155)
New treatments for pulmonary arterial hypertension. (2002) (155)
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study (2006) (153)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study ☆ (2002) (153)
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension (1996) (145)
Treatment of pulmonary arterial hypertension with targeted therapies (2011) (143)
Chemotherapy-induced pulmonary hypertension: role of alkylating agents. (2015) (142)
Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. (2010) (142)
Risk factors for pulmonary arterial hypertension. (2001) (141)
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial (2015) (140)
Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. (2007) (137)
High Plasma Serotonin Levels in Primary Pulmonary Hypertension: Effect of Long-Term Epoprostenol (Prostacyclin) Therapy (2000) (137)
The Fifth World Symposium on Pulmonary Hypertension. (2013) (135)
Appetite-suppressant drugs and the risk of primary pulmonary hypertension (1997) (135)
Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. (2011) (135)
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases (2008) (135)
Occult alveolar haemorrhage in pulmonary veno-occlusive disease (2006) (135)
Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension (2006) (131)
High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. (1998) (131)
French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (2019) (130)
Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era (2012) (130)
Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension (2016) (127)
Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension (2006) (126)
Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. (2012) (124)
Pulmonary arterial resistance: noninvasive measurement with indexes of pulmonary flow estimated at velocity-encoded MR imaging--preliminary experience. (1999) (124)
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. (2016) (123)
Correction: Updated clinical classification of pulmonary hypertension (Journal of the American College of Cardiology (2013) 62, (D34-D41)) (2014) (122)
Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. (2012) (122)
Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension (2017) (122)
Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. (2012) (121)
Factors Influencing Pulmonary Volumes and CO2 Elimination during High‐frequency Jet Ventilation (1985) (121)
Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. (2015) (119)
Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. (2006) (118)
Evidence-Based Clinical Practice Guidelines (2004) (117)
Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. (2015) (115)
Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma. (2013) (113)
Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. (2009) (113)
Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. (1996) (112)
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension (2012) (111)
Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. (2011) (111)
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension (2009) (111)
Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. (2008) (111)
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. (2001) (111)
Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. (1998) (111)
Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension (2009) (110)
Initial dual oral combination therapy in pulmonary arterial hypertension (2016) (109)
Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. (2012) (109)
Treatment of pulmonary hypertension secondary to connective tissue diseases (1999) (108)
Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension: Critical Role for Serotonin-Induced Smooth Muscle Hyperplasia (2006) (107)
Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension (2013) (105)
Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension (2008) (105)
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors (2017) (105)
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. (2017) (104)
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. (2010) (104)
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. (2012) (103)
Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. (2000) (103)
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. (2011) (103)
Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. (2002) (103)
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. (2012) (101)
Primary pulmonary hypertension associated with the use of fenfluramine derivatives. (1998) (100)
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2022) (100)
Chronic thromboembolic pulmonary hypertension: role of medical therapy (2013) (99)
Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension (2013) (99)
Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension (2010) (98)
Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. (2006) (96)
Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease (2009) (96)
Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension (2013) (96)
Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension (2010) (95)
Erratum : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2015) (94)
Subcutaneous Low-Molecular-Weight Heparin Fragmin Versus Intravenous Unfractionated Heparin in the Treatment of Acute Non Massive Pulmonary Embolism: An Open Randomized Pilot Study (1995) (94)
Randomized Trial of Subcutaneous Low‐Molecular‐Weight Heparin CY 216 (Fraxiparine) Compared With Intravenous Unfractionated Heparin in the Curative Treatment of Submassive Pulmonary Embolism: A Dose‐Ranging Study (1992) (93)
Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. (2006) (93)
Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. (1998) (92)
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension (2017) (92)
Evidence-Based Clinical Practice Guidelines Hypertension: Updated ACCP Medical Therapy for Pulmonary Arterial (2007) (90)
Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma (2011) (90)
The CX3C chemokine fractalkine in allergic asthma and rhinitis. (2003) (89)
Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension (2017) (87)
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension (2012) (87)
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats (2010) (87)
Impairment of bronchial mucociliary clearance in long-term survivors of heart/lung and double-lung transplantation. The Paris-Sud Lung Transplant Group. (1993) (87)
A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer (2006) (86)
Genetic counselling in a national referral centre for pulmonary hypertension (2015) (85)
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study (2017) (83)
Drug-induced pulmonary arterial hypertension: a recent outbreak (2013) (83)
Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension (2012) (82)
Transforming growth factor beta in normal human lung: preferential location in bronchial epithelial cells. (1994) (82)
Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension (2007) (82)
Pulmonary veno-occlusive disease: recent progress and current challenges. (2010) (81)
Future perspectives for the treatment of pulmonary arterial hypertension. (2009) (81)
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. (2002) (80)
Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease (2015) (79)
Influence of donor characteristics on outcome after lung transplantation: a multicenter study. (2005) (79)
Key Role of the Endothelial TGF-β/ALK1/Endoglin Signaling Pathway in Humans and Rodents Pulmonary Hypertension (2014) (79)
Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. (2015) (78)
Pulmonary hypertension associated with benfluorex exposure (2012) (78)
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. (2018) (77)
Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension (2011) (77)
Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. (1999) (76)
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients (2012) (76)
Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension (2009) (76)
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? (2009) (75)
ACCP Evidence-Based Clinical Practice Guidelines (2004) (74)
Fenfluramine-like cardiovascular side-effects of benfluorex (2009) (74)
An Extreme Consequence of Splenectomy in Dehydrated Hereditary Stomatocytosis: Gradual Thrombo‐embolic Pulmonary Hypertension and Lung–Heart Transplantation (2003) (74)
Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten Cases (2007) (73)
Validation of two predictive models for survival in pulmonary arterial hypertension (2015) (73)
Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study (2017) (73)
Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. (2007) (73)
Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. (2006) (72)
Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). (1998) (70)
Primary pulmonary hypertension: Current therapy. (2002) (70)
Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? (2013) (69)
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. (2020) (68)
Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. (1997) (68)
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension (2009) (67)
Guidelines on diagnosis and management of acute pulmonary embolism 1 (2000) (67)
Erratum: "Survival with first-line bosentan in patients with primary pulmonary hypertension" (European Respiratory Journal (2005) vol. 25 (244-249)) (2005) (65)
Pulmonary Hypertension in Patients With Neurofibromatosis Type I (2011) (64)
Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis (2002) (63)
Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study (1999) (63)
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study (2018) (63)
Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. (2010) (63)
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. (2014) (62)
Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. (1995) (62)
Pulmonary arterial hypertension in patients treated with interferon (2014) (62)
BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension (2016) (61)
Intrapulmonary production of RANTES during rejection and CMV pneumonitis after lung transplantation. (1996) (61)
Effect of macitentan on hospitalizations: results from the SERAPHIN trial. (2015) (61)
Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases. (2000) (60)
Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. (1999) (59)
Ventilation/perfusion lung scan in pulmonary veno-occlusive disease (2011) (59)
The changing landscape of chronic thromboembolic pulmonary hypertension management (2017) (59)
Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease (2005) (57)
Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. (2012) (57)
Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension (2000) (57)
Long‐term outcome in liver transplantation candidates with portopulmonary hypertension (2017) (56)
Portopulmonary hypertension in the current era of pulmonary hypertension management. (2020) (54)
Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. (2010) (54)
Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study (2015) (53)
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension (2017) (53)
Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry (2018) (53)
Antifibroblast antibodies from systemic sclerosis patients bind to α-enolase and are associated with interstitial lung disease (2009) (53)
Quality of life in patients with chronic thromboembolic pulmonary hypertension (2016) (52)
Liver toxicity of sitaxentan in pulmonary arterial hypertension (2011) (52)
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. (2016) (52)
Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects (2006) (51)
The International Primary Pulmonary Hypertension Study (IPPHS). (1994) (51)
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension (2018) (50)
Surgery Diaphragm dysfunction induced by upper abdominal surgery. Role of postoperative pain Amer. Rev. resp. Dis., 128 (1983) 899–903 (1985) (50)
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. (2021) (49)
Urinary cGMP concentrations in severe primary pulmonary hypertension (1998) (49)
Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. (2012) (49)
Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. (2014) (49)
Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. (2002) (49)
Primary pulmonary hypertension and pregnancy: anesthetic management for delivery. (1988) (48)
Chronic thromboembolic pulmonary hypertension. (2015) (48)
Automatic quantification of right ventricular function with gated blood pool SPECT (2004) (47)
Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. (2016) (47)
Diagnostic value of D-dimer in patients with suspected pulmonary embolism: results from a multicentre outcome study. (2007) (47)
Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. (2014) (46)
The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension (2013) (46)
IN SITU PRODUCTION OF INTERLEUKIN‐6 WITHIN HUMAN LUNG ALLOGRAFTS DISPLAYING REJECTION OR CYTOMEGALOVIRUS PNEUMONIA (1993) (44)
Macitentan Improves Health‐Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (2017) (44)
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN (2015) (44)
The use of combination therapy in pulmonary arterial hypertension: new developments (2009) (44)
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. (2019) (44)
IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction (2011) (43)
Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. (2013) (43)
Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. (2009) (42)
Continuous Infusion of Prostacyclin Decreases Plasma Levels of t-PA and PAI-1 in Primary Pulmonary Hypertension (1995) (42)
Double lung transplantation in situs inversus with Kartagener's syndrome. Paris-Sud University Lung Transplant Group. (1994) (42)
Clinical worsening in trials of pulmonary arterial hypertension: results and implications (2010) (41)
A proof of concept for the detection and classification of pulmonary arterial hypertension through breath analysis with a sensor array. (2013) (41)
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension (2008) (41)
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. (2017) (40)
Use of &bgr;-Blockers in Pulmonary Hypertension (2017) (40)
Association Between Initial Treatment Strategy and Long-term Survival in Pulmonary Arterial Hypertension. (2021) (40)
N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats (2014) (40)
Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics (2016) (40)
Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension (2018) (40)
Improvement of severe pulmonary hypertension in a patient with SLE. (1996) (40)
Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? (2011) (40)
Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre (2009) (39)
Definition and classification of pulmonary hypertension. (2013) (39)
Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation (2012) (39)
Activation of macrophages and cytotoxic cells during cytomegalovirus pneumonia complicating lung transplantations. (1992) (39)
The revised definition of pulmonary hypertension: exploring the impact on patient management (2019) (39)
Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations (2014) (39)
Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. (2019) (38)
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. (2021) (38)
Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. (2005) (38)
Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis (2018) (38)
Pulmonary veno-occlusive disease (2009) (38)
Acute decompensated pulmonary hypertension (2017) (38)
Pulmonary Hypertension Complicating Fibrosing Mediastinitis (2015) (37)
Serum neopterin after lung transplantation. (1993) (37)
Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. (2017) (36)
EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism (2012) (35)
Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution (2009) (35)
Estimating right ventricular stroke work and the pulsatile work fraction in pulmonary hypertension. (2013) (35)
Pulmonary arterial hypertension masquerading as severe refractory asthma (2008) (35)
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension (Annals of Internal Medicine (2008) 149 (521-530)) (2008) (35)
Review: Therapeutic advances in pulmonary arterial hypertension (2008) (35)
Effects Of Inhaled Aviptadil (Vasoactive Intestinal Peptide) In Patients With Pulmonary Arterial Hypertension (PAH) (2010) (34)
Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension (2015) (34)
RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study (2018) (34)
[Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]. (2010) (34)
Liver toxicity of sitaxentan in pulmonary arterial hypertension. (2011) (33)
Sex‐specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry (2020) (33)
Cardiopulmonary effects of a single oral dose of almitrine at rest and on exercise in patients with hypoxic chronic airflow obstruction. (1986) (32)
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. (2015) (32)
Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension (2016) (32)
Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry (2021) (31)
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study (2019) (31)
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension (2019) (31)
Severe pulmonary arterial hypertension in type 1 glycogen storage disease (2007) (31)
Pulmonary arterial hypertension in ANCA-associated vasculitis. (2006) (30)
Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. (2014) (30)
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial (2018) (30)
Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension (2015) (29)
Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension (2016) (29)
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension (2020) (28)
Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. (2017) (28)
Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH (2009) (28)
Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture. (2005) (28)
Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension (2002) (27)
Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure (2016) (27)
New pharmacotherapy options for pulmonary arterial hypertension (2015) (27)
Management of severe pulmonary arterial hypertension (2010) (27)
Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial (2012) (26)
Computation of ventilation-perfusion ratio with Kr-81m in pulmonary embolism. (1984) (26)
[Guidelines for the diagnosis and treatment of pulmonary hypertension]. (2010) (26)
Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. (2013) (26)
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. (2022) (25)
Current management approaches to portopulmonary hypertension (2011) (25)
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment (2013) (25)
The association between resting and mild-to-moderate exercise pulmonary artery pressure (2011) (25)
Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension (2017) (25)
Pulmonary arterial hypertension and HIV infection. (2009) (25)
Sildenafil for pulmonary arterial hypertension: still waiting for evidence. (2004) (25)
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry (2021) (25)
Inhaled iloprost for severe pulmonary hypertension (2002) (24)
Pulmonary arterial hypertension and its association with HIV infection: an overview (2008) (24)
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation (2020) (24)
Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. (2017) (23)
Optimal management of severe pulmonary arterial hypertension (2011) (23)
Factors predicting outcome after pulmonary endarterectomy (2018) (23)
Soluble TNF receptors (TNF-sR55 and TNF-sR75) in lung allograft recipients displaying cytomegalovirus pneumonitis. (1994) (22)
Treatments for severe pulmonary hypertension (1999) (22)
Late Breaking Abstract - Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study (2019) (22)
Mitomycin-Induced Pulmonary Veno-Occlusive DiseaseCLINICAL PERSPECTIVE (2015) (21)
A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. (2017) (21)
Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. (2017) (21)
Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (2012) (21)
Early versus Delayed Introduction of Oral Vitamin K Antagonists in Combination with Low-Molecular-Weight Heparin in the Treatment of Deep Vein Thrombosis (1998) (21)
Riociguat for the Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (CHEST-1) (2012) (21)
Serotonin transporter and receptors in various forms of human pulmonary hypertension. (2005) (20)
Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. (2014) (20)
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study (2017) (20)
EFFICACY AND SAFETY OF CHRONIC SUBCUTANEOUS INFUSION UT-15 IN PULMONARY ARTERIAL HYPERTENSION (PAH) (ABSTRACT 477) (2000) (20)
Fatal dissection of the pulmonary artery in pulmonary arterial hypertension (2009) (20)
PLASMA D-DIMER AND PULMONARY EMBOLISM (1989) (19)
Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. (2017) (19)
[Pulmonary artery hypertension associated with connective tissue diseases]. (2003) (19)
Future perspectives in pulmonary arterial hypertension (2016) (18)
Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. (2018) (18)
Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases (2005) (18)
Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) (2011) (18)
The study of risk in pulmonary arterial hypertension (2012) (18)
[Gas exchange, static pressure-volume curve and positive-pressure ventilation at the end of expiration. Study of 16 cases of acute respiratory insufficiency in adults]. (1981) (18)
A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension (2015) (18)
Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. (2018) (18)
Pulmonary vascular disorders. (2012) (17)
Novel therapeutic perspectives in pulmonary arterial hypertension (2003) (17)
Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease (2018) (17)
[Pulmonary hypertension: CT findings in pulmonary veno-occlusive disease]. (2003) (17)
Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. (2020) (17)
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. (2020) (16)
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. (2017) (16)
Idiopathic pulmonary hypertension: what did we learn from genes? (2005) (16)
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study (2013) (16)
Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation (2020) (16)
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. (2019) (16)
Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension (2018) (16)
Pulmonary hypertension in patients with sickle cell disease: not so frequent but so different (2012) (16)
Association of NT-proBNP and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension: Insights from the Phase III GRIPHON Study (2019) (16)
Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. (2015) (15)
Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease (2019) (15)
A decade of achievement in pulmonary hypertension (2011) (15)
Recombinant hirudin (HBW 023): Biological data of ten patients with severe venous thrombo‐embolism (1995) (15)
Prospective Multicentric Survey On Pulmonary Hypertension (PH) in Adults with Sickle Cell Disease. (2009) (15)
Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. (2021) (14)
Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence (2005) (14)
Diaphragm Dysfunction Induced by Upper Abdominal Surgery (2015) (14)
Pulse wave reflection in pulmonary hypertension. (2002) (14)
Frequency of mechanical ventilation and respiratory activity after double lung transplantation. (1993) (14)
Perspective on the optimal endpoints for pulmonary arterial hypertension trials (2010) (14)
Lack of bronchial hyperresponsiveness to methacholine and to isocapnic dry air hyperventilation in heart/lung and double-lung transplant recipients with normal lung histology. The Paris-Sud Lung Transplant Group. (1992) (14)
Hypertension artérielle pulmonaire postembolique tumorale (2007) (13)
Pulmonary arterial hypertension: bridging the present to the future (2012) (13)
[Pulmonary arterial hypertension of chronic thrombo-embolic origin. 70 patients]. (1994) (13)
Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. (2010) (13)
Pulmonary venoocclusive disease and failure of specific therapy. (2009) (13)
Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure (2012) (13)
A comparative study of the cardiorespiratory effects of continuous positive airway pressure breathing and continuous positive pressure ventilation in acute respiratory failure (1982) (13)
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. (2017) (13)
Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension (2017) (13)
Effect of age on the performance of a diagnostic strategy based on clinical probability, spiral computed tomography and venous compression ultrasonography (2005) (13)
Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. (2016) (13)
Vasodilators in patients with chronic obstructive pulmonary disease and pulmonary hypertension: not ready for prime time! (2010) (13)
Treatment of pulmonary arterial hypertension. (2004) (12)
Results of the FREEDOM–C Study: A Pivotal Study of Oral Treprostinil Used Adjunctively with an ERA and/or PDE5-Inhibitor for the Treatment of PAH. (2009) (12)
Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry (2018) (12)
Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension (2015) (12)
Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension (2011) (12)
Snoring and Obstructive Sleep Apnea: Objective Efficacy and Impact of a Chairside Fabricated Mandibular Advancement Device (2017) (12)
Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group. (1998) (12)
A single orally administered dose of almitrine improves pulmonary gas exchange during exercise in patients with chronic air-flow obstruction. (1986) (11)
Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension (2002) (11)
The Beneficial Effect of Suramin on Monocrotaline-Induced Pulmonary Hypertension in Rats (2013) (11)
Inhibition of gastric alcohol dehydrogenase activity by histamine H2-receptor antagonists has no influence on the pharmacokinetics of ethanol after a moderate dose. (1994) (11)
Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. (2018) (11)
Developing a heart score: next steps. (2012) (11)
Diaphragm Dysfunction Induced by Upper Abdominal Surgery. Role of Postoperative Pain (1985) (10)
Soluble interleukin 2 receptor and neopterin serum levels after lung/heart-lung transplantations--absence of predictive value for late allograft rejection. (1991) (10)
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications (2017) (10)
[Pulmonary thromboendarterectomy with video-angioscopy and circulatory arrest: an alternative to cardiopulmonary transplantation and post-embolism pulmonary artery hypertension]. (1998) (10)
CD74-Dependent Interleukin-6 And Monocyte Chemoattractant Protein-1 Secretion By Pulmonary Endothelial Cells In Idiopathic Pulmonary Hypertension (2012) (10)
[Pulmonary arterial hypertension due to tumor emboli]. (2007) (10)
[A new clinical classification of pulmonary hypertension]. (2009) (9)
Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension (2018) (9)
Riociguat for pulmonary hypertension. (2013) (9)
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. (2021) (9)
Intramuscular triamcinolone in severe asthma. (1991) (9)
Late-breaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension (2014) (9)
[Treatments for pulmonary arterial hypertension]. (2004) (9)
Preoperative C-Reactive Protein Predicts Early Postoperative Outcomes after Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension (2019) (9)
Upfront Triple Combination Therapy Of I.V. Epoprostenol With Oral Bosentan And Sildenafil In Idiopathic And Heritable Pulmonary Arterial Hypertension (2011) (9)
Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. (2022) (9)
Efficacy, Safety And Tolerability Of ACT-293987, A Novel Oral, Non-prostanoid, Prostaglandin I2 (IP) Receptor Agonist: Results From A Phase IIa Study In Pulmonary Arterial Hypertension (PAH) (2010) (9)
Hypertension pulmonaire : définition, diagnostic et nouvelle classification (2014) (8)
Transforming growth factor in normal human lung: preferential location in bronchial epithelial cells (8)
Computed Tomography Findings Of Pulmonary Veno-Occlusive Disease In Scleroderma Patients Presenting With Precapillary Pulmonary Hypertension (2012) (8)
Perforin and granzyme B gene-expressing cells in bronchoalveolar lavage fluids from lung allograft recipients displaying cytomegalovirus pneumonitis. (1994) (8)
ACCP Evidence-Based Clinical Practice Guidelines Surgical Treatments / Interventions for Pulmonary Arterial Hypertension (2004) (8)
Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. (2021) (8)
SITAXSENTAN, A SELECTIVE ENDOTHELIN-A RECEPTOR ANTAGONIST, IMPROVES EXERCISE CAPACITY IN PULMONARY ARTERIAL HYPERTENSION (PAH) ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (CTD) (2005) (8)
Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. (2016) (8)
[Pulmonary hypertension and obesity]. (2002) (8)
Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France (2020) (8)
Effects of Acid Infusion into the Esophagus on Airflow Obstruction and Bronchial Hyperreactivity in Adult Asthmatic Patients (1985) (7)
Rare (pulmonary) disease day: “feeding the breath, energy for life!” (2015) (7)
Phenotype and outcome of PAH patients carrying a TBX4 mutation. (2020) (7)
Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems (2020) (7)
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) (2013) (7)
Imatinib Improves Exercise Capacity and Hemodynamics at 24 Weeks as Add-on Therapy in Symptomatic Pulmonary Arterial Hypertension Patients: The IMPRES Study (2011) (7)
Hemoptysis in Pulmonary Arterial Hypertension (PAH): A Life-Threatening Complication. (2009) (7)
[Genetics of pulmonary arterial hypertension: recent data and practical applications]. (2005) (7)
Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) (2014) (7)
[Clinical, haemodynamic and genetic features of familial pulmonary arterial hypertension]. (2004) (7)
Chronic Thromboembolic Pulmonary Hypertension Associated With Indwelling Port-A-Cath® Central Venous Access Systems (2011) (7)
Future Directions in Chronic Thromboembolic Pulmonary Hypertension. Disease at a Crossroads? (2016) (7)
Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy (2013) (7)
[Treatment for pulmonary arterial hypertension under the new French hospital financing system. Recommendations of the Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine]. (2005) (7)
The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension (2014) (7)
External validation of the REVEAL risk score calculator for PAH survival: A French pulmonary hypertension network analysis (2012) (7)
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. (2020) (7)
Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. (2020) (7)
Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. (2015) (7)
Safety of Therapeutic Doses of Tinzaparin During Pregnancy (2015) (6)
[Pulmonary hypertension due to left heart diseases]. (2018) (6)
Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH (2020) (6)
The French registry of pulmonary arterial hypertension in children: rationale and design (2007) (6)
An insider view on the World Symposium on Pulmonary Hypertension. (2019) (6)
PULMONARY HYPERTENSION ASSOCIATED WITH SARCOIDOSIS: mechanisms, hemodynamics and (2005) (6)
Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? (2015) (6)
[Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension]. (2008) (6)
Bosentan for human immunodeficiency virus-associated pulmonary arterial hypertension (2004) (6)
[Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin]. (2016) (6)
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases (2019) (6)
[Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications]. (1994) (6)
Mediastinal fibrosis mimicking proximal chronic thromboembolic disease. (2012) (6)
Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. (2021) (6)
Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". (2016) (6)
BOSENTAN IMPROVES HEMODYNAMICS IN PATIENTS RECEIVING BACKGROUND SILDENAFIL TREATMENT: RESULTS FROM EARLY, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH MILDLY SYMPTOMATIC PULMONARY ARTERIAL HYPERTENSION (2007) (6)
Pulmonary arterial hypertension (2004) (6)
Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) (2018) (6)
Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials (2012) (6)
Ganciclovir treatment of cytomegalovirus infection in heart-lung and double-lung transplant recipients. (1991) (6)
The changing picture of patients with pulmonary arterial hypertension (PAH) in France (2011) (6)
Improving patient outcomes in pulmonary hypertension (2015) (6)
[Pulmonary hypertension complicating systemic diseases other than connective tissue diseases]. (2003) (6)
[Pulmonary hypertension: definition, diagnostic and new classification]. (2014) (5)
Association between Leflunomide and Pulmonary Hypertension. (2021) (5)
Catheter Related-infections In Pulmonary Hypertension Patients Treated By Continuous Intravenous Epoprostenol: Experience Of The French Referral Centre (2010) (5)
Hypertension artérielle pulmonaire primitive (2002) (5)
Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study (2020) (5)
Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension (2016) (5)
Impact Of Pulmonary Arterial Hypertension Specific Therapy On Portopulmonary Hypertension (2010) (5)
Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. (2011) (5)
EPITOME-2, An Open-Label Study Evaluating A New Formulation Of Epoprostenol Sodium In Pulmonary Arterial Hypertension Patients Switched From Flolan® (2012) (5)
A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica (2016) (5)
Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study (2017) (5)
Survival improved in systemic sclerosis associated pulmonary arterial hypertension patients aged 70 years or less over the period 2006-2017 in France. (2019) (5)
Prevalence and Mechanism of Pulmonary Hypertension in Sickle Cell Disease: A Prospective Multicentre French Study. (2009) (5)
Traitement chirurgical de l’hypertension pulmonaire post-embolique (2014) (5)
Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice (2010) (5)
[Rupture of the healthy stomach following gaseous distension (author's transl)]. (1981) (5)
Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story. (2017) (5)
TADALAFIL IMPROVES EXERCISE CAPACITY, HEALTH RELATED QUALITY OF LIFE AND DELAYS TIME TO CLINICAL WORSENING IN PATIENTS WITH SYMPTOMATIC PULMONARY ARTERIAL HYPERTENSION (PAH) (2008) (5)
A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study (2019) (4)
Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study (2015) (4)
[Pulmonary hypertension associated with systemic sclerosis]. (2002) (4)
Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry (2015) (4)
FACTORS INFLUENCING TIDAL VOLUME DURING HIGH-FREQUENCY JET VENTILATION (1984) (4)
An Interim Analysis Of Long-Term Outcomes In Patients Treated With Bosentan In The Double-Blind Or Open-Label Extension To The Early Trial (2011) (4)
Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy (2014) (4)
[The Fifth World Symposium on Pulmonary Hypertension]. (2014) (4)
External validation of the French predictive model to estimate PAH survival: A REVEAL analysis (2012) (4)
Reply: pulmonary hypertension of sickle cell disease beyond classification constraints. (2014) (4)
[Primary pulmonary artery hypertension (data of the literature and personal experience with 25 cases in 10 years)]. (1991) (4)
Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial (2013) (4)
Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension. (2019) (4)
Long-term Riociguat Treatment in Inoperable and Persistent/Recurrent CTEPH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 16-Week Phase III CHEST-1 Study and CHEST-2 Open-Label Extension (2014) (4)
New Perspectives for Treatment of Pulmonary Embolism (1998) (4)
Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy (2013) (4)
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors (2016) (4)
A paradigm shift in pulmonary arterial hypertension management (2013) (4)
Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities (2019) (4)
Human immunodeficiency virus infection in transplant recipients. (1986) (4)
Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension". (2015) (4)
REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal (2017) (4)
Rationale and Study Design of the RESPITE Trial: Riociguat Clinical Effects Studied in Pulmonary Arterial Hypertension (PAH) Patients With Insufficient Treatment Response to PDE-5 Inhibitors (PDE-5i) (2015) (4)
[Nodular regenerative hyperplasia and pulmonary arterial hypertension]. (1990) (4)
Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) (2018) (3)
Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population (2015) (3)
A roadmap for management of chronic thromboembolic pulmonary hypertension (2019) (3)
Prevalence Of Chronic Thrombo-embolic Pulmonary Hypertension After Acute Pulmonary Embolism : A Prospective Multicenter Study (2010) (3)
[Pulmonary hypertension. Major therapeutic advances]. (2008) (3)
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. (2020) (3)
Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension (2006) (3)
Pulmonary Hypertension In Patients Treated By Dasatinib (2012) (3)
New horizons in pulmonary arterial hypertension management (2014) (3)
The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH) (2019) (3)
SERIES "ADVANCES IN PATHOBIOLOGY, DIAGNOSIS, AND TREATMENT OF PULMONARY HYPERTENSION" Edited by A.T. Dinh-Xuan, M. Humbert, R. Naeije Number 10 in this Series Chronic thromboembolic pulmonary hypertension (2004) (3)
[Investigation of pulmonary hypertension]. (2008) (3)
Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) (2013) (3)
Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry (2016) (3)
[Hilar adenopathy compressing the pulmonary arteries in the course of sarcoidosis]. (2007) (3)
Nilotinib And Imatinib Therapy In Experimental Pulmonary Hypertension (2012) (3)
Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study (2017) (3)
Are indexed values better for defining exercise pulmonary hypertension? (2017) (3)
Sustained effect of macitentan, a novel oral endothelin receptor antagonist, on exercise capacity and the association of its measure with long-term outcomes in pulmonary arterial hypertension (2013) (3)
Pulmonary Arterial Hypertension Associated With Pulmonary Langerhans Cell Histiocytosis: Impact Of Pulmonary Hypertension Therapy (2011) (3)
Recurrent Thromboembolism in Two Unrelated Patients with Double Heterozygosity for Factor V R506Q and Factor II 20210G/A Mutations (1998) (3)
Chronic Thromboembolic Pulmonary Hypertension: Results From A Prospective, Observational European Registry (2010) (3)
The evolving landscape of pulmonary arterial hypertension clinical trials (2022) (3)
Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. (2022) (3)
FRI0245 Survival and prognostic factors in patients with incident systemic sclerosis-associated pulmonary arterial hypertension from the french registry (2011) (3)
Upfront Combination Therapy With Ambrisentan and TadalafilIin Treatment Naive Patients With Pulmonary Arterial Hypertension (PAH): Subgroup Analyses by Functional Class (FC), Etiology, and Region From the AMBITION Study (2014) (3)
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study (2020) (3)
Circulating Dendritic Cells in Idiopathic Pulmonary Arterial Hypertension and Cirrhotic Portopulmonary Hypertension. (2009) (3)
Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan (2013) (3)
Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic BMPR2 mutation carriers (DELPHI-2 Study) (2019) (3)
Efficacy and safety of macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): Results from the randomized controlled MERIT study (2018) (3)
ARTIFICIAL VENTILATION AND PULMONARY CAPILLARY WEDGE PRESSURE IN ACUTE RESPIRATORY FAILURE (1976) (3)
Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of ACVRL1 (ALK1) Mutation. (2009) (3)
[Acute respiratory insufficiency during diffuse lipoid pneumopathy]. (1978) (3)
Safety of Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension: Final Data Cut from the EXPERT Registry (2019) (3)
Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. (2015) (3)
Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL (2017) (3)
SITAXSENTAN IMPROVES TIME TO CLINICAL WORSENING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (2005) (3)
Prophylactic treatment of post-operative thrombosis: a meta-analysis of the results from trials assessing various methods used in patients undergoing major orthopaedic (hip and knee) surgery (1993) (3)
Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH) (2015) (3)
[Heart-lung transplantation and double lung transplantation. 33 cases]. (1991) (3)
Subcutaneous low molecular weight heparin (fragmin) versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open pilot study (1992) (3)
Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study (2013) (3)
Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension (2012) (3)
Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. (2021) (3)
Phosphodiesterase inhibitors for pulmonary hypertension. (2010) (2)
Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function (2018) (2)
Long-term Outcomes of Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease as Compared With Idiopathic or Heritable Pulmonary Arterial Hypertension Treated With Tadalafil (2011) (2)
Primary Pulmonary Hypertension and Pregnancy: Anesthetic Management for Delivery (1989) (2)
[Pulmonary veno-occlusive disease]. (2018) (2)
Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study (2016) (2)
Macitentan and pulmonary arterial hypertension. (2014) (2)
The Therapeutic Potential Of The Renin-Angiotensin-Aldosteron System In Idiopathic Pulmonary Arterial Hypertension (2012) (2)
A New Definition Of Exercise Induced Pulmonary Hypertension (2012) (2)
[HIV-related pulmonary arterial hypertension]. (2012) (2)
Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021 (2023) (2)
OP0267 Initial Combination Therapy of Ambrisentan and Tadalafil in Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH): Subgroup Analysis from the Ambition Trial (2015) (2)
Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST-1 study (2013) (2)
EPITOME-2: Evaluation of a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from an originally approved formulation (2012) (2)
Validation Of The French Pulmonary Hypertension Network Equation To Estimate Survival: A REVEAL Analysis (2012) (2)
Effect of macitentan on haemodynamics in patients with pulmonary arterial hypertension: results from the long-term, randomised, placebo-controlled SERAPHIN trial (2013) (2)
Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high‐priority allocation program (2021) (2)
Comparing cardiac magnetic resonance imaging in group 1 and group 4 pulmonary hypertension (2011) (2)
[Pulmonary arterial hypertension and sickle cell disease]. (2013) (2)
Clinical Outcomes of PAH Patients Walking More Than 450m in 6-Min at the Time of Diagnosis. (2009) (2)
[Chronic pulmonary heart disease: therapeutic indications]. (1995) (2)
Risk categories from European guidelines applied to the French Pulmonary Hypertension (PH) registry (2017) (2)
Positive end-expiratory vs negative external pressure mechanical ventilation during pulmonary edema in dogs. (1981) (2)
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results (2015) (2)
Long-Term Oral Sildenafil Added To Intravenous Epoprostenol Therapy Improves Outcomes In Patients With Pulmonary Arterial Hypertension (2010) (2)
Role for dysregulated endothelium- derived FGF2 signaling in progression of pulmonary hypertension (2008) (2)
[Surgical treatment of chronic thromboembolic pulmonary hypertension]. (2005) (2)
mutation type on clinical phenotypes of pulmonary arterial hypertension (2010) (2)
Management of selexipag interruptions in the GRIPHON study (2016) (2)
Early selexipag initiation and long-term outcomes: Insights from RCTs in PAH (2022) (2)
Safety of Riociguat for the Treatment of Pulmonary Arterial Hypertension: Final Data Cut from the EXPERT Registry (2019) (2)
Markers of endothelial involvement in chronic pulmonary hypertension (1994) (2)
[A gene for primary pulmonary artery hypertension]. (2001) (2)
Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study (2020) (2)
Outcome of Heart-Lung or Double-Lung Transplantation in Pulmonary Hypertension Secondary to Congenital Heart Diseases (2018) (2)
Pulmonary hypertension related to appetite suppressants (2011) (2)
INITIAL TREATMENT COMBINATION WITH MACITENTAN AND TADALAFIL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE OPTIMA STUDY (2019) (2)
Effects of 12-week exercise training-related rehabilitation on exertional dyspnoea in patients with idiopathic pulmonary arterial hypertension (2015) (2)
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension (2021) (1)
108 Endothelin-1 and Endothelin-3 plasma levels in severe pulmonary arterial hypertension (2005) (1)
Chronic thromboembolic pulmonary hypertension associated with Klippel Trenaunay syndrome: A retrospective series of 5 patients (2011) (1)
Contribution of increased afterload to right ventricular ejection fraction in pulmonary hypertension (2011) (1)
Effects of broad spectrum tyrosin kinase inhibitor on pulmonary circulation homeostasis (2013) (1)
Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study (2013) (1)
Idiopathic pulmonary arterial hypertension in the elderly: Data from the French registry (2011) (1)
[Diagnosis and care of postembolic pulmonary hypertension: the role of the pneumologist]. (2008) (1)
Severe pulmonary arterial hypertension in type 1 glycogen storage disease (2002) (1)
Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139]. (2020) (1)
Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study (2017) (1)
The Relationship Between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients With PAH Not Reaching Treatment Goals With Phosphodiesterase 5 Inhibitors (2016) (1)
Classification of Pulmonary Hypertension (2014) (1)
Assessment of the REPLACE Study Composite Endpoint in the PATENT Study and Association with Long-Term Outcomes in Riociguat-Treated Patients (2019) (1)
Outcome of candidates for liver transplantation suffering from portopulmonary hypertension (2013) (1)
Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model (2017) (1)
Bone Marrow Derived C-kit Positive Cells In Pulmonary Arterial Hypertension (2010) (1)
HIV-Associated Pulmonary Arterial Hypertension: Survival and Prognostic Factors in the Current Therapeutic Era. (2009) (1)
[Gayet-Wernicke encephalopathy with initial coma, hyperglycemia, acido-ketosis, and disorders of the respiratory control-system]. (1977) (1)
Measurement of tidal volume during high frequency jet ventilation by an external spirometric method (1984) (1)
Six-Years Experience With High Priority Allocation Program for Lung and Heart-Lung Transplantation in Pulmonary Hypertension (2015) (1)
Correcting For Age And Sex Unmasks Decreased Right Ventricular Ejection Fraction In Pulmonary Hypertension (2011) (1)
[Postembolic pulmonary hypertension]. (2007) (1)
Chemosensitivity and ventilatory inefficiency in pulmonary vascular diseases (2017) (1)
World Health Organization classification and risk factors for pulmonary arterial hypertension (2004) (1)
Combined Pulmonary Fibrosis and Emphysema with Associated Pulmonary Hypertension: Characteristics and Prognostic Determinants. (2009) (1)
CORRELATION OF WHO FUNCTIONAL CLASS AND INDICES OF DISEASE SEVERITY IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM EARLY, BREATHE-1 AND 351 STUDIES (2006) (1)
Nadroparin 0.3 mL Versus Enoxaparin 40 mg in the Prevention of Venous Thromboembolism in Abdominal Surgery for Colorectal Cancer: A Randomized Double-Blind Comparative Study. (2005) (1)
Is there an obesity paradox in pulmonary arterial hypertension (2017) (1)
EFFECT OF MACITENTAN ON HEMODYNAMICS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: Results FROM THE LONG-TERM, RANDOMISED, PLACEBO-CONTROLLED SERAPHIN TRIAL (2014) (1)
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension (2013) (1)
[Pulmonary hypertension associated with connective tissue diseases]. (2002) (1)
Basic (PS01–PS58) (2012) (1)
[Pulmonary hypertension during systemic diseases. Classification problems]. (2003) (1)
IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension (2015) (1)
Pulmonary hypertension in lymphangioleiomyomatosis: Hemodynamic characteristics in a series of 20 patients (2011) (1)
Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease (2011) (1)
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension (2008) (1)
LATE-BREAKING ABSTRACT: KCNK3 dysfunction contributes to the development of pulmonary arterial hypertension – Characterization of Kcnk3 deficient rats (2016) (1)
SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE (PAH-CHD) AFTER DEFECT CORRECTION: INSIGHTS FROM THE RANDOMISED CONTROLLED GRIPHON STUDY (2016) (1)
Adverse reactions with anistreplase (1991) (1)
Immune repertoire-based signatures in pre-capillary pulmonary hypertension (2018) (1)
S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (pah): insights from the randomised controlled griphon trial with selexipag (2016) (1)
Involvement of the pulmonary micro-vasculature in chronic thromboembolic pulmonary hypertension (CTEPH) (2012) (1)
P16 Treatment of VTE during pregnancy with a once-daily regimen of LMWH (2009) (1)
Five-years experience with high urgency allocation program for lung and heart-lung transplantation in pulmonary hypertension (2014) (1)
, Hypertension Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial (2005) (1)
[Strategies for utilization of anticoagulants in pulmonary embolism]. (1999) (1)
Accuracy of transpulmonary thermodilution cardiac output measurement (PiCCO) in patients with right heart failure (RHF) due to precapillary pulmonary hypertension (PH) (2013) (1)
P130Cas-Dependent Reversal Of Pulmonary Arterial Muscularization By Imatinib, Gefitinib And Dovitinib (2012) (1)
[Effect of artificial ventilation on pulmonary capillary pressure in acute respiratory insufficiency]. (1977) (1)
MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension (2013) (1)
[What is your diagnosis? Thoracic extramedullary hematopoiesis in a patient with beta-thalassemia]. (2007) (1)
Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy (2018) (1)
Atrial septal fenestration in children for treatment of end-stage pulmonary hypertension (2007) (1)
The Angle Between The Interventricular Septum And The Left Ventricular Free Wall As A New Index Of Right Ventricular Overload In Pulmonary Hypertension Patients: A Cardiac Magnetic Resonance Study (2011) (1)
3016Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension (2018) (1)
Associated With Connective Tissue Disease Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension (2006) (1)
Krypton 81m ventilation/perfusion ratios (V/Q) measured in lateral decubitus in pulmonary embolism (P. E. ) (1984) (1)
Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study (2017) (1)
SWITCHING TO RIOCIGUAT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION NOT AT TREATMENT GOAL WITH PHOSPHODIESTERASE TYPE-5 INHIBITORS: SUBGROUP ANALYSIS RESULTS OF THE REPLACE STUDY (2020) (1)
Hypertension artérielle pulmonaire associée à l'infection par le VIH (2009) (1)
Influence of continuous infusion of prostacyclin on plasma levels of t-PA, PAI-1 and vWF in primary pulmonary hypertension (1994) (0)
Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era (2015) (0)
Diagnostic et prise en charge de l’hypertension pulmonaire postembolique : le rôle du pneumologue (2008) (0)
Bosentan in mild pulmonary hypertension – Authors' reply (2008) (0)
Joint Annual Meeting of the Swiss Society for Allergology and Immunology and the Swiss Respiratory Society, Bern, April 17-19, 2013 (2013) (0)
Therapeutic aspects of pulmonary embolism (2004) (0)
Absence Of Gamma-herpesvirus Infection In Patients With Pulmonary Arterial Hypertension (2010) (0)
breathlessness during exercise with advancing age Sex differences in the perceived intensity of (2015) (0)
Genetic counselling in pulmonary arterial hypertension: Experience from the French referal centre (2011) (0)
Radionuclide Angiographic Assessment of Right Ventricular Ejection Fraction Is Pronostic in Pulmonary Arterial Hypertension (2013) (0)
LATE-BREAKING ABSTRACT: Vascular endothelial cells in pulmonary arterial hypertension express a unique spectrum of volatile organic compounds (2016) (0)
Do respiratory mechanics abnormalities contribute to exertional dyspnoea in patients with pulmonary hypertension (2011) (0)
Frequency and impact on prognosis of signs of pulmonary veno-occlusive disease on high resolution computed tomography in patients with scleroderma associated pulmonary arterial hypertension (2011) (0)
Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHIN (2013) (0)
[Heart-lung transplantation]. (1987) (0)
Long-Term Safety, Efficacy And Survival Outcomes Of Pulmonary Arterial Hypertension In WHO Functional Class II Patients Treated With Bosentan (2012) (0)
Abstract 18517: GCN2 Dysfunction at the Heart of Pulmonary Veno-Occlusive Disease Development (2016) (0)
16.46 Impact of the etiology of pulmonary hypertension on right ventricular function: primary pulmonary hypertension versus chronic post-embolic pulmonary hypertension (2001) (0)
[Acute respiratory failure: comparison of spontaneous ventilation with continuous positive airway pressure (CPAP) and mechanical ventilation with positive and expiratory pressure (CPPV) in 6 cases (author's transl)]. (1979) (0)
Balloon pulmonary angioplasty (BPA) for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) (2018) (0)
Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension (2015) (0)
Papers Related to Obesity Surgery for 1996 (1997) (0)
4.45 Prediction of operative mortality of pulmonary thrombo-endarterectomy in patients with chronic post-embolic pulmonary hypertension: value of right-ventricular function and hemodynamic parameters (2001) (0)
262. Physiology of human pulmonary hypertension (2011) (0)
EFFECT OF RIOCIGUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (2018) (0)
Appetite suppressants and pulmonary hypertension (1997) (0)
[Surgical treatment of post-embolism pulmonary hypertension]. (2004) (0)
[What is your diagnosis?]. (2007) (0)
Pulmonary arterial lesions and interstitial remodeling patterns in histology differentiate EIF2AK4 mutation-carriers from non-carriers with pulmonary veno-occlusive disease (2015) (0)
Contents Vol. 85, 2013 (2013) (0)
Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era (2018) (0)
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension (2016) (0)
Dexamethasone Reverses Vascular Remodelling in Monocrotaline Pulmonary Arterial Hypertension. (2009) (0)
Iconography : Chronic thromboembolic pulmonary hypertension (2015) (0)
S94 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON (2021) (0)
Increased p130Cas activity induces smooth muscle cell proliferation and migration in idiopathic pulmonary arterial hypertension (2011) (0)
Lung and circulating immune cell repertoires in PAH (2013) (0)
Phenotype and outcome of PAH patients carrying a TBX4 mutation (2020) (0)
0425: Prognostic value of invasive hemodynamic parameters in Eisenmenger syndrome (2015) (0)
Right Ventricular Function Is Related To Resistive Rather Than To Elastic Pulmonary Arterial Properties In Precapillary Pulmonary Hypertension: A Cmr Study (2014) (0)
Exercise capacity : from elite athletes to severe impairment P 839 Factors predicting exercise-induced oxygen desaturation in stable COPD (2012) (0)
OE-108 Tadalafil Improves Exercise Capacity in Patients with Pulmonary Arterial Hypertension (PAH) : a Randomized, Double-blind, Placebocontrolled, Multinational Phase III Study(OE19,Pulmonary Circulation (H),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Japanese Circulation (2009) (0)
Assessment of the REPLACE study composite endpoint in the PATENT study and association with long-term outcomes in riociguat-treated patients. (2020) (0)
An interim analysis of the phase III riociguat long-term extension study in CTEPH (CHEST-2) (2013) (0)
Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON (2020) (0)
16.48 Can ECG-gated blood pool tomography be used for the evaluation of the severity and in the follow-up of patients with chronic post-embolic pulmonary hypertension (2001) (0)
Changes in red blood cell membrane structure in pulmonary arterial hypertension (2016) (0)
Pulmonary hypertension associated with portal hypertension (2011) (0)
[Pulmonary arterial hypertension]. (2005) (0)
SERIES ''PULMONARY HYPERTENSION: BASIC CONCEPTS FOR PRACTICAL MANAGEMENT'' Edited by M.M. Hoeper and A.T. Dinh-Xuan Number 7 in this Series Pulmonary veno-occlusive disease (2009) (0)
[Introduction. Pulmonary arterial hypertension]. (2010) (0)
[Evaluation in man of the hemodynamic and respiratory effects of positive-expiratory-pressure spontaneous respiration (CPAP)]. (1981) (0)
Small airways dysfunction in chronic thromboembolic pulmonary hypertension (2015) (0)
Devenir des patients candidats à une transplantation hépatique et atteints d’hypertension porto pulmonaire (2013) (0)
Risk Factors and Coagulation Disorders – LMWH Pharmacokinetics and Pharmacodynamics (1998) (0)
Characteristics of PAH associated with pretricuspid shunts in the French PAH registry (2011) (0)
Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story? (2017) (0)
The Relationship of Hemodynamics and Exercise Capacity With Response to Riociguat Therapy in the Respite Study of PAH Patients With an Insufficient Response to Phosphodiesterase 5 Inhibitors (2017) (0)
Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) (2013) (0)
S152 Dexamethasone reverses established monocrotaline-induced pulmonary hypertension in rats and increases pulmonary BMPR2 expression (2010) (0)
S122 Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension (2018) (0)
Prognostic value of changes in radionuclide right ventricular ejection fraction in pulmonary arterial hypertension (2013) (0)
[Surgical treatment of chronic thromboembolic pulmonary hypertension]. (2014) (0)
Screening pulmonary hypertension by lung doppler signal: A proof-of-concept study (2015) (0)
Precapillary Pulmonary Hypertension With Pulmonary Vessel Involvement In Lymphangioleiomyomatosis (2012) (0)
Cardiac output by direct Fick, thermodilution and modelflow in pre-capillary pulmonary hypertension (2014) (0)
Poor Subpleural Perfusion as a predictor of Failure after Balloon Pulmonary Angioplasty for non-operable Chronic Thromboembolic Pulmonary Hypertension (2017) (0)
Abstract 12841: Mutations in the BMPR2 Gene Are Associated With Worse Survival in Patients With Pulmonary Arterial Hypertension (2015) (0)
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications (2017) (0)
Transplantation for Pulmonary Arterial Hypertension with Congenital Heart Disease: Impact of current therapeutic approach including a high-priority allocation programme on outcomes (2021) (0)
Chronic thromboembolic and pulmonary arterial hypertension share right ventricular and pulmonary artery CMR features. (2019) (0)
TCT-89 Balloon pulmonary angioplasty for chronic thromboembolic hypertension: report of a two-year experience in a surgical center. (2016) (0)
New formula for predicting mean pulmonary artery pressure. Author's reply (2005) (0)
Biological assessment of various Low Molecular Weight Heparins (LMWH) in patients with thromboembolic disease (1992) (0)
Using controlled and real-world data in concert to assess survival in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL (2018) (0)
Hypoxia Pulmonary Arterial Hypertension : Results of a Multicenter European Analysis of Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial (2009) (0)
epithelial cells . bronchialhuman lung : preferential location in Transforming growth factor beta in normal (0)
Pulmonary arterial hypertension associated with fenfluramine exposure : report of 109 cases. Commentary (2008) (0)
[Surgical treatment of pulmonary arterial hypertension]. (2011) (0)
What does really measure the respiratory inductive plethysmograph (1983) (0)
Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan (2013) (0)
Clinical Classification of Pulmonary Hypertension. Authors' reply (2010) (0)
Recurrence ofpulmonary embolism during anticoagulant treatment: aprospective study (1987) (0)
The total cross-sectional area of bronchial arteries predicts the extent of persistent PH after endarterectomy (2019) (0)
Whistleblowers (2011) (0)
Other Uses of LMWHs – Miscellaneous (1998) (0)
095 Monocyte chemotactic protein-1 (CCL2/ MCP-1) synthesis and rôle in idiopathic pulmonary arterial hypertension (IPAH) (2005) (0)
mbrisentan Therapy for ulmonary Arterial Hypertension (0)
Complement-Binding Anti-HLA Antibodies and Kidney Transplantation (2014) (0)
From the authors: (2011) (0)
Lung capillary blood volume and membrane diffusion in PH (2014) (0)
5022Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease (2017) (0)
[Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?]. (2011) (0)
Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension Running title: Ranchoux et al.; EndoMT in pulmonary hypertension (2015) (0)
Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2 (2016) (0)
Clinical phenotypes and outcomes of pulmonary veno-occlusive disease in carriers of bi-allelicEIF2AK4mutations (2016) (0)
Front & Back Matter (2012) (0)
[Post-embolic pulmonary arterial hypertension: therapeutic indications]. (1995) (0)
Pulmonary Hypertension in Sickle Cell Disease (2012) (0)
Anti-Vascular Smooth Muscle Cell Antibodies in the Serum of Patients with Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Bind to Cytoskeleton, Oxidative Stress and Cell Cycle Antigens. (2009) (0)
Evaluation of differential linear transformers as a non-invasive ventilatory method in supine subjects. (1986) (0)
Thromboprophylaxis in Pregnancy, Orthopaedic Surgery Patients and in Long-Term Strategies (1998) (0)
Heart Rate Accurately Reflects Mean Pulmonary Artery Pressure In Pulmonary Hypertension Patients Performing Mild-To-Moderate Exercise (2012) (0)
Clinical features of pulmonary hypertension (2011) (0)
Immune signatures in pulmonary arterial hypertension (2014) (0)
Abstract 12334: A Flavor of Metabolic Disease in Pulmonary Hypertension (2015) (0)
Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry (2017) (0)
Abstract 12186: Therapeutic Effects of Blockade of IL-6/gp130 Signaling in Pulmonary Arterial Hypertension (2015) (0)
Evidence-Based Clinical Practice Guidelines : Updated ACCP * Hypertension Medical Therapy for Pulmonary Arterial (2007) (0)
Letter: Artificial ventilation and pulmonary capillary wedge pressure in acute respiratory failure. (1976) (0)
BONE MORPHOGENETIC PROTEIN SIGNALING IN HERITABLE VERSUS IDIOPATHIC PULMONARY HYPERTENSION BMP signaling in Pulmonary Hypertension (2009) (0)
Results Presence of Cells With a Mixed Mesenchymal / Endothelial Phenotype in Intimal and Plexiform Lesions of PAH Lungs (2015) (0)
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension (2022) (0)
Bone Morphogenetic Protein Signaling in Familial Versus Idiopathic Pulmonary Arterial Hypertension (2009) (0)
[Pulmonary artery hypertension: therapeutic progress]. (2003) (0)
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib (2011) (0)
[Diagnosis and classification of pulmonary arterial hypertension]. (2005) (0)
16.47 Right and left ventricular interaction in chronic post-embolic pulmonary hypertension: a model for predicting the limits of normal left ventricular ejection fraction (2001) (0)
Venous Remodeling And Distal Pulmonary Arteriopathy Are Frequently Present In CTEPH (2012) (0)
Pulmonary hypertension associated with neurofibromatosis type 1: data from the French Pulmonary Hypertension Registry (2019) (0)
[Positive end expiratory pressure and pulmonary compliance during acute respiratory insufficiency]. (1979) (0)
335 Characteristics of PAH associated with pretricuspid shunts in the registry of the French PAH network (2012) (0)
Cervical nystagmus. Sign of proprioceptive interference with vestibular function (1980) (0)
IMPACT OF BASELINE RISK STATUS ON OUTCOMES IN THE REPLACE STUDY (2021) (0)
P2540Sex-specific differences in the clinical presentation, surgical complications, and course of chronic thromboembolic pulmonary hypertension (2019) (0)
P2614Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era (2018) (0)
Screening of pulmonary arterial hypertension in BMPR2 mutation carriers (2020) (0)
Non-invasive ventilation in COPD LEARNING POINTS * Acidosis is an important prognostic factor for exacerbations of respiratory failure in COPD . * (0)
276: Potts’ shunt in children with idiopathic pulmonary arterial hypertension: long-term results (2013) (0)
ORIGINAL ARTICLE Antibodies to fibroblasts in idiopathic and scleroderma associated pulmonary hypertension (2006) (0)
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension (2023) (0)
Genetic Counselling In The French Pulmonary Hypertension Referral Center (2012) (0)
Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal (2015) (0)
Role for Dysregulated Endothelium-Derived FGF2 Signaling in Progression of Pulmonary Hypertension. (2009) (0)
Abstracts, Oral communications, Tuesday, 3 September 2002 (2002) (0)
Characteristics and outcomes of heritable pulmonary veno-occlusive disease due toEIF2AK4mutations (2015) (0)
330 Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the registry of the French PAH network (2012) (0)
Evidence-Based Clinical Practice Guidelines Medical Therapy For Pulmonary Arterial Hypertension : ACCP (2004) (0)
[Lung transplantation]. (1988) (0)
Prostanoid Treatment for Pulmonary Arterial Hypertension (2008) (0)
[Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial]. (2008) (0)
096 Endothelin-1 expression and effects on pulmonary artery smooth muscle cells in idiopathic pulmonary arterial hypertension (IPAH) (2005) (0)
Altered endothelin-1 (ET1) synthesis and ET1 receptors expression and function in idiopathic pulmonary hypertension : Influence of BMPRII mutations (2007) (0)
[Antithrombotic therapy for venous thromboembolism - report of the 7th Conference of The American College of Chest Physicians]. (2005) (0)
An Open-Label Extension Trial Of UT-15C SR In Subjects With Pulmonary Arterial Hypertension -- Interim Results Of Patients From Freedom - C (2011) (0)
p53-dependent, replicative cell senescence suppresses chronic hypoxia-Induced pulmonary hypertension in mice (2011) (0)
Iconography : Hypertension artérielle pulmonaire (2009) (0)
Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry (2011) (0)
[Deep venous thrombosis and pulmonary embolism]. (2002) (0)
Guidelines on the identification and treatment of pulmonary hypertension. (2009) (0)
Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH) (2020) (0)
[Comparison of various methods of prevention of venous thrombosis in orthopedics]. (1992) (0)
Current strategies for managing CTEPH (2021) (0)
[Perspectives on pulmonary vascular diseases]. (2005) (0)
[Calculation of the ventilation-perfusion ratio in the scintigraphic diagnosis of pulmonary embolism]. (1987) (0)
La transplantation coeur-poumons. (1987) (0)
Pulmonary thromboendarterectomy (PTE) in chronic thromboembolic pulmonary hypertension (CTE-PH): Impact on LV and RV function (1999) (0)
[2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. (2023) (0)
Detection of Antibodies to Tenascin-C in Patients with Idiopathic Pulmonary Arterial Hypertension. (2009) (0)
Right ventricular afterload and myocardial oxygen demand during exercise in pulmonary hypertension (2011) (0)
[Economic assessment of the use of tinzaparin in the treatment of acute pulmonary embolism in France]. (2001) (0)
Outcomes of patients with precapillary pulmonary hypertension admitted to an intensive care unit for acute right heart failure (2017) (0)
SAFETY AND EFFICACY OF MACITENTAN IN ELDERLY PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM SERAPHIN (2020) (0)
Switching from PDE5i to riociguat in patients with PAH: A responder analysis from REPLACE (2021) (0)
Prognostic value of hemodynamics following treatment initiation in pulmonary arterial hypertension (2017) (0)
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) (2016) (0)
Abstract 12206: Endothelial-derived Mif Contributes to Pulmonary Endothelial Cell Proliferation in Human Pulmonary Arterial Hypertension (2015) (0)
Systematic Analysis of Arterial, Capillary and Venous Involvement in Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease. (2009) (0)
Short title: Bosentan in portopulmonary hypertension (2012) (0)
Equilibrium ECG-gated Tc-99m SPECT radionuclide angiography (RNA) in chronic thromboembolic pulmonary hypertension (CTE-PH) (1999) (0)
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice (2015) (0)
[Lung transplantation]. (1989) (0)
Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network (2015) (0)
Association between Leflunomide and Pulmonary Hypertension (2021) (0)
16.52 Validation of an “echocardiography-like” method for right- ventricular function evaluation applied to ECG-gated blood pool tomography (2001) (0)
Contents Vol. 79, 2015 (2015) (0)
Characteristics and outcome of patients with pre-capillary pulmonary hypertension who were drained for tamponade: A monocentric study (2013) (0)
Biological changes following infusion of recombinant hirudin (HBW 023) in 10 patients with severe thromboembolism (1992) (0)
ResearchAbsence of influence of gender and BMPR 2 mutation type on clinical phenotypes of pulmonary arterial hypertension (2010) (0)
[Rejection reaction and use of rifampicin in the treatment of tuberculosis in kidney transplantation]. (1985) (0)
Inspiratory muscle constraint during exercise in patients with pulmonary arterial hypertension (2012) (0)
Pulmonary hypertension: its assessment and treatment (1999) (0)
Recent Advances in Pulmonary Hypertension (2014) (0)
[Ventilation with expiratory positive pressure protects against the harmful effects of cardiac output increase]. (1979) (0)
Management of Decompensated COPD (1987) (0)
[Pulmonary arterial hypertension]. (2008) (0)
Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR) (2020) (0)
Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2) (2020) (0)
[Measurement of arterio-alveolar CO2 difference in pulmonary embolism]. (1980) (0)
Epoprostenol Therapy as a Life Saving Bridge to Lung Transplantation for Pulmonary Veno-Occlusive Disease. (2009) (0)
Granulysin in pulmonary veno-occlusive disease (2013) (0)
Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data (2018) (0)
[Elementary principles of hemodynamics in the use of the balloon catheter. Applications in anesthesia and resuscitation]. (1977) (0)
Outcomes Following Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension in Octogenarians (2015) (0)
Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the French PAH registry (2011) (0)
Chronic thrombo-embolic pulmonary hypertension (2018) (0)
0481 : Potassium channel subfamily K member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension (2016) (0)
Editors' perspective and conclusions. (2008) (0)
Explorative breath analysis study for the detection and classification of PAH (2013) (0)
Prolonged haloperidol induced Parkinsonism in a patient with cirrhosis (2008) (0)
Clinical Characteristics And Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Diagnosed By A Systematic Detection Program (2011) (0)
A comparative histological study of pulmonary vascular lesions in lungs of patients with idiopathic or heritable PAH (2013) (0)
Clinical and haemodynamic predictors of abnormal pulmonary vascular response at exercise (2015) (0)
Nebivolol and pulmonary hypertension (2014) (0)
[Eisenmenger syndrome. Role of rare diseases reference centers in the management of pulmonary hypertension in congenital heart diseases]. (2009) (0)
P4005Poor subpleural perfusion as a predictor of failure after balloon pulmonary angioplasty for non-operable chronic thromboembolic pulmonary hypertension (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gérald Simonneau?

Gérald Simonneau is affiliated with the following schools:

Gérald Simonneau's Academic­Influence.com Rankings

Why Is Gérald Simonneau Influential?

Gérald Simonneau's Published Works

Published Works

What Schools Are Affiliated With Gérald Simonneau?

Gérald Simonneau's AcademicInfluence.com Rankings